Seven Fleet Capital Management LP Acquires New Stake in Century Therapeutics, Inc. $IPSC

Seven Fleet Capital Management LP bought a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,347,826 shares of the company’s stock, valued at approximately $9,826,000. Century Therapeutics accounts for 3.1% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 4th largest holding.

Other large investors have also recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new stake in shares of Century Therapeutics in the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp acquired a new position in shares of Century Therapeutics during the first quarter worth about $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Century Therapeutics during the second quarter worth about $38,000. Quadrant Private Wealth Management LLC grew its holdings in shares of Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after buying an additional 4,736 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the second quarter worth about $51,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC opened at $2.02 on Friday. Century Therapeutics, Inc. has a 52-week low of $0.44 and a 52-week high of $3.04. The company has a market capitalization of $364.31 million, a P/E ratio of -1.77 and a beta of 1.55. The company has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $2.23.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. As a group, equities analysts forecast that Century Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on IPSC. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Mizuho initiated coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Finally, HC Wainwright boosted their price objective on shares of Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.75.

Century Therapeutics Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.